Abstract:Rationale: Synergic reprogramming of metabolic dominates neuroblastoma (NB) progression. It is of great clinical implications to develop an individualized risk prognostication approach with stratification-guided therapeutic options for NB based on elucidating molecular mechanisms of metabolic reprogramming. Methods: With a machine learning-based multi-step program, the synergic mechanisms of metabolic reprogramming-driven malignant progression of NB were elucidated at single-cell and metabolite flux dimensions. Subsequently, a promising metabolic reprogramming-associated prognostic signature (MPS) and individualized therapeutic approaches based on MPS-stratification were developed and further validated independently using pre-clinical models. Results: MPS-identified MPS-I NB showed significantly higher activity of metabolic reprogramming than MPS-II counterparts. MPS demonstrated improved accuracy compared to current clinical characteristics [AUC: 0.915 vs. 0.657 (MYCN), 0.713 (INSS-stage), and 0.808 (INRG-stratification)] in predicting prognosis. AZD7762 and etoposide were identified as potent therapeutics against MPS-I and II NB, respectively. Subsequent biological tests revealed AZD7762 substantially inhibited growth, migration, and invasion of MPS-I NB cells, more effectively than that of MPS-II cells. Conversely, etoposide had better therapeutic effects on MPS-II NB cells. More encouragingly, AZD7762 and etoposide significantly inhibited in-vivo subcutaneous tumorigenesis, proliferation, and pulmonary metastasis in MPS-I and MPS-II samples, respectively; thereby prolonging survival of tumor-bearing mice. Mechanistically, AZD7762 and etoposide-induced apoptosis of the MPS-I and MPS-II cells, respectively, through mitochondria-dependent pathways; and MPS-I NB resisted etoposide-induced apoptosis by addiction of glutamate metabolism and acetyl coenzyme A. MPS-I NB progression was fueled by multiple metabolic reprogramming-driven factors including multidrug resistance, immunosuppressive and tumor-promoting inflammatory microenvironments. Immunologically, MPS-I NB suppressed immune cells via MIF and THBS signaling pathways. Metabolically, the malignant proliferation of MPS-I NB cells was remarkably supported by reprogrammed glutamate metabolism, tricarboxylic acid cycle, urea cycle, etc. Furthermore, MPS-I NB cells manifested a distinct tumor-promoting developmental lineage and self-communication patterns, as evidenced by enhanced oncogenic signaling pathways activated with development and self-communications. Conclusions: This study provides deep insights into the molecular mechanisms underlying metabolic reprogramming-mediated malignant progression of NB. It also sheds light on developing targeted medications guided by the novel precise risk prognostication approaches, which could contribute to a significantly improved therapeutic strategy for NB.

Neuroblastoma and its Targets Therapies: A Medicinal Chemistry Review

Development of Differentiation Modulators and Targeted Agents for Treating Neuroblastoma.

Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventions

Advancing therapy for neuroblastoma

High-Risk Neuroblastoma Challenges and Opportunities for Antibody-Based Cellular Immunotherapy

From the identification of actionable molecular targets to the generation of faithful neuroblastoma patient-derived preclinical models

Nanotechnology-Based Diagnostic and Therapeutic Strategies for Neuroblastoma

Targeting the ubiquitin-proteasome system: a novel therapeutic strategy for neuroblastoma

Advances in the approaches used to repurpose drugs for neuroblastoma

Recent advances in the developmental origin of neuroblastoma: an overview

The neuroblastoma tumor microenvironment: From an in-depth characterization towards novel therapies

Calcium-Regulatory Proteins As Modulators of Chemotherapy in Human Neuroblastoma

Neuroblastoma: clinical and biological approach to risk stratification and treatment

Preclinical spheroid models identify BMX as a therapeutic target for metastatic MYCN nonamplified neuroblastoma

Combined inhibition of histone methyltransferases EZH2 and DOT1L is an effective therapy for neuroblastoma

Developing targeted therapies for neuroblastoma by dissecting the effects of metabolic reprogramming on tumor microenvironments and progression

Current Knowledge and Perspectives of Immunotherapies for Neuroblastoma

TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI

Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives

Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors

Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma